US › Healthcare

Biomea Fusion Inc (BMEA)

US · Healthcare · Biotechnology

$1.23+2.50%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-12.4M
Profit YoY
+57.6%
EPS
$-0.17
EPS estimate
$-0.19

EPS came in at -0.17 against a street estimate of -0.19 — a beat of 10.5%.

Key statistics

Market cap
$86.8M
Forward P/E
0.0
P/B
4.52
Book value
$0.26
EPS (TTM)
$-0.55
52-week high
$2.99
52-week low
$0.87
50-day MA
$1.29
200-day MA
$1.37
Beta
-0.30

Analyst view

Analysts rate Biomea Fusion Inc a buy (7 buy, 2 hold, 0 sell out of 9) with an average price target of $6.83.

Shareholding

Insiders
7.17%
Institutions
39.13%

Largest institutional holders

FundStake
FMR Inc12.19%
Vanguard Capital Management, LLC3.59%
Aisling Capital Management LP2.83%
Renaissance Technologies Corp1.82%
Marshall Wace Asset Management Ltd1.66%
Fideuram - Intesa Sanpaolo Private Banking Spa1.00%
Citadel Advisors Llc0.91%
Mariner Wealth Advisors LLC0.91%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Biomea Fusion Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.